Combination Cell Therapy's Clinical Success Hinges On Manufacturability

By Sanjeev Luther, CEO, Ernexa Therapeutics

The cell and gene therapy industry has advanced in its understanding of biology. Researchers now design therapies that not only target the disease directly but also reshape the immune system, modify the tumor microenvironment, and complement other treatments.

Some of the most promising advances come from combination strategies. In oncology, checkpoint inhibitors have improved treatment for many tumor types, but some solid tumors remain resistant due to limited immune access or activation. Cell therapies may help overcome this by creating conditions that enhance the effectiveness of checkpoint inhibitors. Unlike hematologic malignancies, solid tumors often require therapies capable of trafficking into hostile tumor microenvironments and maintaining activity over time, increasing the importance of manufacturing consistency.

Ernexa's recent preclinical findings support this approach. As developers see more encouraging results from combination therapies, a key question arises: How can we ensure these therapies reach patients? For companies entering first-in-human studies, manufacturing strategy is now as important as therapeutic strategy.

Combination Therapies Are Changing How Developers Think About Cell Therapy

The growing interest in combining cell therapies with checkpoint inhibitors reflects a broader shift in oncology. Increasingly, researchers recognize that many cancers are not resistant because the immune system is incapable of recognizing malignant cells. Rather, the tumor microenvironment actively suppresses immune activity, preventing effective anti-tumor responses.

Checkpoint inhibitors have demonstrated that removing inhibitory signals can unlock meaningful clinical benefit in some patients. However, many solid tumors remain largely unresponsive because there are insufficient numbers of activated immune cells present within the tumor in the first place. This has led researchers to explore whether cell therapies can serve as complementary tools that help establish the conditions necessary for checkpoint inhibitors to achieve their full therapeutic potential. This is fueling growing interest in cell therapies engineered to recruit and activate endogenous immune cells, deliver therapeutic proteins directly within the tumor, and convert immunologically cold tumors into hot ones that are more responsive to checkpoint blockade.

For developers, this evolution represents more than a scientific opportunity. It introduces a new set of development and manufacturing requirements. A therapy designed to be part of a combination regimen must not only demonstrate its own biological activity but also do so consistently enough for investigators to understand how each component contributes to the overall treatment effect. That places a premium on process control, product characterization, and manufacturing reproducibility from the earliest stages of development.

As more companies pursue strategies that combine cell therapies with checkpoint inhibitors, cytokines, bispecific antibodies, and other immuno-oncology approaches, the industry's ability to manufacture these products reliably may become just as important as the underlying biology. Combinations already advancing in the clinic illustrate the range of these approaches, including CAR T cell therapy paired with checkpoint inhibitors, mesenchymal stromal cell (MSC)-based cytokine delivery combined with PD-1 blockade, and cell therapies used alongside bispecific antibodies. Each pairing raises its own manufacturing questions, but all depend on a cell therapy component that performs consistently enough to be evaluated as part of a broader regimen.

Biological Innovation Alone Is Not Enough

Historically, many cell therapy programs followed a straightforward progression: establish proof of concept in preclinical models, demonstrate biological activity, and then focus on manufacturing optimization as the program advanced. While that approach may have been feasible in earlier generations of cell therapy development, it is increasingly difficult to sustain today. Investors, regulators, clinical investigators, and development partners all expect greater confidence that a promising therapy can ultimately be manufactured at scale and delivered consistently to patients.

Combination immunotherapies add complexity. Developers must now create products that integrate reliably into broader treatment regimens, often with checkpoint inhibitors, targeted therapies, or other immune-modulating agents.

Therefore, manufacturing considerations must be addressed much earlier in the development process.

Questions that once seemed operational now become strategic:

• Can the product be produced consistently across batches?
• Can manufacturing support multicenter clinical trials?
• Can supply chains accommodate patient demand if clinical results are positive?
• Can production economics support eventual commercialization?

The answers to these questions can determine whether a promising therapy progresses or stalls.

Scalability Must Be Designed In Early

A key lesson in the cell therapy sector is that scalability must be considered from the outset.

Autologous therapies have shown significant clinical benefit in several hematologic malignancies, but they also present challenges with individualized manufacturing. Patient-specific production increases logistical complexity, scheduling constraints, and scalability limitations, especially as therapies expand to larger patient populations.

This reality is driving growing interest in allogeneic platforms. An allogeneic approach enables manufacturing larger product quantities in a single run, building inventory ahead of patient need, and simplifying logistics for clinical sites. These off-the-shelf, inventory-based platforms are particularly well-suited for large-batch production and rapid deployment across multiple clinical sites, reducing dependence on the patient-specific manufacturing workflows that constrain autologous approaches. However, realizing these benefits requires significant investment in process development, quality systems, and manufacturing controls well before commercialization.

The priority is not just choosing an allogeneic platform but building manufacturing processes that maintain product consistency while enabling scale. Companies that delay these investments may need to redesign core manufacturing processes during clinical development, increasing risk and potential regulatory complications.

Scalability planning should also account for what happens after an encouraging clinical signal emerges. Positive early-stage data often leads to expanded cohorts, additional trial sites, new indications, or accelerated development timelines. Manufacturing systems that are designed solely to support an initial first-in-human study may struggle to keep pace with these demands.

For this reason, developers should think beyond immediate clinical needs and evaluate whether their processes can scale without fundamentally altering the product itself. Significant manufacturing changes introduced after clinical activity has been demonstrated may require extensive comparability assessments and can introduce additional regulatory complexity. Building scalability into the platform early can help reduce those risks and create a more efficient development pathway.

Supply Chain Readiness Starts Before Clinical Proof Of Concept

Many organizations see supply chain planning as a commercial-stage issue. In reality, decisions made during preclinical development often determine future success. For cell therapies, supply chain considerations go far beyond raw material procurement. Developers must think about:

• critical reagent availability,
• manufacturing capacity planning,
• cryopreservation strategies,
• distribution logistics,
• chain-of-identity and chain-of-custody requirements, and
• long-term supplier relationships.

Each component can create potential bottlenecks. Recent disruptions in the biopharmaceutical industry have shown how vulnerable advanced therapy programs are to supply interruptions. A single constrained raw material can delay manufacturing and clinical timelines.

Cell source qualification becomes particularly important because sourcing decisions made early in development often have long-term implications. Likewise, developers should assess critical reagent availability not only for current manufacturing requirements but also for future clinical expansion. A supplier that can support a small preclinical program may not be able to meet the needs of a multicenter clinical trial or eventual commercial launch.

Organizations should also evaluate cryopreservation and distribution strategies well before clinical studies begin. As therapies expand into larger geographic footprints and additional treatment centers, logistical complexity can increase significantly. Establishing resilient supply chain frameworks early can help prevent operational challenges from becoming development delays later.

Organizations preparing for first-in-human studies should assess supply chain resilience as rigorously as they evaluate clinical development plans.

Manufacturing Must Support The Mechanism Of Action

One lesson emerging across advanced therapy development is that manufacturing strategy cannot be separated from therapeutic design. The manufacturing process ultimately determines whether the product delivered to patients faithfully reflects the biological mechanism established during preclinical research.

This challenge becomes particularly important for cell therapies intended to influence the tumor microenvironment. Unlike traditional therapies that rely primarily on systemic exposure, many next-generation cell therapies are designed to perform highly specific functions within localized disease settings. Those functions may include trafficking to tumors, secreting therapeutic proteins, recruiting immune cells, or altering local immune signaling pathways. These approaches are increasingly viewed as a path to improving responsiveness to checkpoint inhibitors in solid tumors that have otherwise proven resistant.

Each of these mechanisms creates additional expectations for product characterization. Developers must establish analytical methods that demonstrate that the manufactured product retains the attributes necessary to achieve its intended biological effect. Identity, purity, potency, viability, stability, and functional activity all become critical elements of the development strategy.

In practice, this means process development teams and translational research teams must work closer together than has historically been the case. Manufacturing decisions made during early development can influence product performance months or years later in the clinic. Conversely, a deeper understanding of the mechanism of action can help teams identify which product attributes warrant the most rigorous monitoring and control during manufacturing.

Combination Therapies Raise The Bar For Consistency

When cell therapy is combined with another therapeutic modality, manufacturing consistency becomes even more critical. For example, checkpoint inhibitors are administered with well-defined dosing and quality standards. Cell therapy developers must ensure their products offer similar batch-to-batch reliability so investigators can accurately assess treatment effects. Consider a CAR-T program combined with a checkpoint inhibitor or an MSC-based cytokine-delivery platform paired with PD-1 blockade: in both cases, any run-to-run variability in the cell product can be mistaken for a change in the clinical effect of the combination, making it harder to attribute outcomes to either component.

Variability that is manageable in exploratory settings can become problematic when evaluating combination regimens. This places greater emphasis on:

• robust analytical characterization,
• clearly defined release criteria, process control strategies, and
• manufacturing reproducibility.

Developers must also establish analytical frameworks that demonstrate consistent biological activity across production runs. Potency assays, functional characterization methods, and release testing strategies become increasingly important as combination regimens move through clinical development. Without these tools, it can be difficult to distinguish manufacturing variability from genuine clinical variability.

Consistently producing the intended biological effect is essential for clinical success.

Preparing For The Next Generation Of Immunotherapy

The future of cancer treatment will likely involve more sophisticated combinations of therapeutic modalities. Cell therapies, checkpoint inhibitors, cytokine-based approaches, and other immunotherapies may work together to address mechanisms that single interventions cannot overcome.

While scientific advances are exciting, the industry's next challenge may be building the manufacturing infrastructure needed to deliver these innovations reliably and at scale. Successful organizations will treat manufacturing as a core component of therapeutic design, not just a downstream operational function.

For developers approaching first-in-human studies, the key question is no longer just whether a therapy works in preclinical models but whether the platform can support the journey from discovery to patient access. As combination immunotherapies mature, this distinction will become increasingly important.

About The Author:

Sanjeev Luther is president and CEO of Ernexa Therapeutics and a member of the board of directors. He is a seasoned pharmaceutical executive with over 30 years in leadership roles at organizations including Cornerstone Pharmaceuticals, Bristol Myers Squibb, Novartis, Bausch and Lomb, and GE Healthcare. Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease.